ANTI-ALARMIN BINDING MOLECULES AND TREATMENT OF PNEUMONITIS

The present disclosure provides methods and compositions for the treatment of pneumonitis (including checkpoint inhibitor induced pneumonitis), fibrosis, and type 2 inflammatory disorders comprising administering anti-alarmin binding molecules to a subject in need thereof. In some embodiments treatm...

Full description

Saved in:
Bibliographic Details
Main Authors WHITE, Daniel, SWANSEN, Sven, NIKOLINOKOS, Petros, JACKSON, Crystal
Format Patent
LanguageEnglish
French
Published 07.12.2023
Subjects
CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Online AccessGet full text

Cover

More Information
Summary:The present disclosure provides methods and compositions for the treatment of pneumonitis (including checkpoint inhibitor induced pneumonitis), fibrosis, and type 2 inflammatory disorders comprising administering anti-alarmin binding molecules to a subject in need thereof. In some embodiments treatment comprises administering one or more checkpoint inhibitors conjugated to a therapeutic moiety comprising a cytotoxic agent, a therapeutic agent, a radioisotope, an ultrasound sensitizer, or an exosome secretion inhibitor. La présente divulgation concerne des méthodes et des compositions pour le traitement de la pneumonite (y compris la pneumonite induite par un inhibiteur de point de contrôle), la fibrose et des troubles inflammatoires de type 2 comprenant l'administration de molécules de liaison anti-alarmine à un sujet qui en a besoin.
Bibliography:Application Number: WO2023US63267